In summary, the IL-33/ST2 pathway promotes progression of breast cancer in both pre-clinical and clinical studies mostly through the recruitment of inflammatory cells that enhance tumor growth, invasiveness, and angiogenesis. Here, IL1RL1 is linked to neoplasm.